Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: A retrospective cohort study at FUSCC

PURPOSE: Neoadjuvant therapy (NAT) is considered the standard of care for patients with HER2-positive breast cancer (BC). However, there is no proven survival benefit of NAT compared to adjuvant therapy for the survival of patients with early-stage HER2-positive BC. This study aimed to compare the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Shuyue, Li, Lun, Chen, Ming, Yang, Benlong, Chen, Jiajian, Liu, Guangyu, Shao, Zhimin, Wu, Jiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038764/
https://www.ncbi.nlm.nih.gov/pubmed/35429731
http://dx.doi.org/10.1016/j.breast.2022.03.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038764/
https://www.ncbi.nlm.nih.gov/pubmed/35429731
http://dx.doi.org/10.1016/j.breast.2022.03.015

Ejemplares similares